Drug
Insulin Glargine
Insulin Glargine: highest development phase Post-Market, developed by Eli Lilly, Sanofi. 3 trial records tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Eli Lilly, Sanofi
Trials
| Drug | Phase | Indication |
|---|---|---|
| INSULIN GLARGINE NCT00576368 | Post-Market | Diabetes Mellitus |
| SOLIQUA 100/33 | Approved | |
| Insulin glargine NCT00447213 | Phase 2/3 | Diabetes Mellitus, Type 1 |
Latest
No recent events.
Follow Insulin Glargine on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.